1. Platelet survival and an index of the localization of platelets in the kidney were studied in patients with the proliferative nephritis of systemic lupus erythematosus, either focal or diffuse, and in control subjects. Platelet survival was reduced in patients with proliferative lupus nephritis, more in those with diffuse rather than focal renal involvement.
Introduction
There is ample evidence that human platelets undergo aggregation and release in the presence of some immune complexes (Bettex-Galland & Luscher, Mustard, 1964; Movat, Mustard, Taichman & Urinhara, 1965) . The relation of this reaction to renal damage in vivo has been explored by Kniker & Cochrane (1968) in acute glomerulonephritis produced in the rabbit by the injection of a single large dose of bovine serum albumin. In this now classical model of acute immune complex-induced renal damage, a marked reduction in the localization of antigen-antibody complexes in the glomeruli, inhibition of glomerular lesions and of proteinuria were demonstrated, when circulating platelets were depleted by the use of a powerful anti-platelet antiserum, or when antagonists of platelet vasoactive amines were given.
1964;
The human prototype of immune complex nephritis-systemic lupus erythematosus (Koffler, Agnello, Thoburn & Kunkel, 1971 )-has a more protracted and insidious course of renal involvement, which can often be determined by the initial morphological classification of the renal lesion (Baldwin, Lowenstein, Rothfield, Gallo & McCluskey, 1970 ; J. S. Cameron, unpublished work; Pollack, Pirani & Schwartz, 1964) .
Therefore we undertook the study of platelet survival and renal platelet localization in patients with proliferative lupus nephritis to determine if intrarenal platelet consumption correlated with the spectrum of future renal impairment noted for the proliferative forms of lupus nephritis.
In addition, a patient with idiopathic thrombocytopenic purpura was assessed to compare the platelet localization pattern in a patient with platelet consumption secondary to autoantibody sensitization (Karpatkin, Strick, Karpatkin & Siskind, 1972 ) with our patients with systemic lupus erythematosus.
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Methods
Patients
All subjects gave their informed consent for the study. One patient had idiopathic thrombocytopenic purpura based on the criteria of Doan, Bouponcle & Wiseman (1960) . Twelve patients, aged 24-54 years, had glomerulonephritis secondary to systemic lupus erythematosus. Three were male and nine were female. Eleven of the twelve met the preliminary criteria of the American Rheumatism Association for the diagnosis of systemic lupus erythematosus (Cohen & Canoso, 1972 ) and all gave positive results for anti-nuclear factor, human tissue being used as a substrate in an immunofluorescent technique (Cameron, Vick, Ogg, Seymour, Chantler & Turner, 1973) with DNA binding by the Farr technique (Hughes, 1971 ) greater than 30% on at least one occasion. Nine of these patients had episodes of hypocomplementaemia characterized by low serial C4 and C3 concentrations measured by radial immunodiffusion (Cameron et al., 1973) . All patients had a renal biopsy and the appearances were classified by one of us (J.S.C.) without knowledge of the platelet studies as focal proliferative glomerulonephritis or as diffuse proliferative glomerulonephritis, the descriptive criteria of Baldwin et al. (1970) being used. Details of the immunological and clinical features of the patients at the time of the study and the biopsy classification are provided in Table 1 .
Control subjects. Six healthy volunteers aged from 28 to 39 years were studied. Apart from symptomless gout in one subject, all were arthritis-free and had no known renal disease.
Platelet survival
Labelling, sampling, separation and radioactivity assay. Autologous platelets were separated from blood taken into citric acid-citrate-dextrose, and labelled in vitro with NaZ5lCrO4 with the method described by Dacie & Lewis (1968) but performed at 20°C. Because of the severe thrombocytopenia, isologous platelets were used in the patient with idiopathic thrombocytopenic purpura. Blood samples were taken after injection of the labelled platelets at 30 min to 1 h and then daily for up to 7 days. Separation of the circulating platelets was performed by differential centrifugation, ammonium oxalate erythrocyte lysis and repeated washing. The 'Cr radioactivity of the washed and separated platelets was assayed in a Packard gamma spectrometer type 5319. Calculations. Platelet survival was determined from the disappearance of platelet 'Cr radioactivity separated from blood samples taken over periods of up to 7 days. The highest radioactivity within 24 h of injection was taken as 100% (Kotilainen, 1969) . When the disappearance curve plotted on arithmetic paper was linear (four control subjects, eight patients), survival was determined by simple extension to zero activity; when it was curvilinear (two control subjects, four patients), the initial slope was extrapolated visually to zero (Harker & Finch, 1969; Paulus, 1971 ). In the case of the patient with idiopathic thrombocytopenic purpura the disappearance patterns were described by a single exponential function and survival was calculated by dividing the half-time of disappearance by log.2 (Harker & Finch, 1969) .
The recovery of labelled platelets remaining within the systemic circulation was calculated from the formula: platelet activity of initial sampling multiplied by the blood volume (estimated from body weight) and divided by the 51Cr radioactivity injected (Aster, 1966) .
Renal platelet localization
Surface radioactivity counting. This was done with a J and P Engineering MS 3 10 counter, rate meter and pulse-height analyser connected to a 4.3 cm detector crystal with parallel collimation to a depth of 5.8 cm and aperture diameter of 7.8 cm.
Counting was performed daily for the first 5 days of the platelet survival study over kidney and spleen. The selection of a ratio between two organs to express radioactivity rather than absolute counts was based on the need to eliminate the artifacts of individual variation of platelet pool labelled as well as removing the consideration of 'Cr decay and daily variances in the sensitivity of the recording apparatus.
The selection of right rather than left kidney was based on the absolute radioactivity counts taken over heart, liver, spleen, right and left kidney in our first Mean valuesf SD of the ratios for four control subjects are shown.
Ratio
Liver at t+/liver at day 0 1.0k0.2 R. kidney at t j/R. kidney at day 0 Heart at t+/heart at day 0 L. kidney at t*/L. kidney at day 0 0.7k0.1 07k0.1 1.0k0.3 l.l+O.l Spleen at tj/spleen at day 0 four control subjects. Absolute counts were two to three times greater over left than right kidneys. Thus to assess the degree of background radiation we compared individual organ activity at t+ days of platelet survival with that at day 0. t+ was determined directly from the platelet survival curves (Fig. 1 and  Fig. 2) . It was apparent that radioactivity counts over the left kidney were significantly influenced by the very high splenic activity whereas measurements over the right kidney revealed no evidence of interference from the liver and correlated favourably with the heart ratio ( Table 2) .
The spleen was selected as the organ of comparison since there were data from other localization studies on splenic activity with which to compare our results (Aster, 1966; Aster & Keene, 1969) .
This ratio of right kidney over spleen was then correlated at t+ days and at day 0 of platelet survival to provide a comparable index of renal platelet localization.
This comparison of ratios (Kotilainen, 1969) served to reduce variability due to differences in body habitus, platelet survival and renal blood flow between subjects.
Results
Platelet survival
Recoveries of platelets (mean values k SD) were: control subjects, 65 +20%; patients with systemic lupus erythematosus, 55 + 15%; patient with idiopathic thrombocytopenic purpura, 70%. Platelet survival was 9.4 days (SD +O-5, n = 6) in the control subjects. The eight patients with a diffuse proliferative glomerulonephritis on biopsy showed a significant reduction in platelet survival (6.3 SD f 1.1 days, .4 days, n = 4; P <0.02). Platelet survival was significantly shorter in the diffuse proliferative subjects than in those patients with focal proliferative disease ( Table 3) . The patient with idiopathic thrombocytopenic purpura had a platelet survival of 0.8 day.
Renal platelet localization
The renal platelet localization ratio for five control subjects was 0.50 (s~kO.17, n = 5). The eight patients with diffuse proliferative disease had a significant increase ( P < 0.01) in renal platelet localization with a ratio of 1.07 (SD k 0.26, n = 8), and the ratio in three patients with focal lesions was 0.85 ( s~k 0 . 2 5 , n = 3). There was a significant difference in mean platelet localization ratio between control subjects and patients with diffuse proliferative disease but not in the patients with focal lesions ( P < 0.2) ( Table 4) .
The renal platelet localization in the patient with idiopathic thrombocytopenic purpura was markedly reduced and was 0.04.
Discussion
Because of great difficulty in identifying remnants of platelets which have undergone aggregation and release in tissue (Stoltzher, Dzoga & Wissler, 1972) , the role of the platelet in human renal disease has received little attention. Studies in animals (Kniker & Cochrane, 1968; Henson & Cochrane, 1971) , however, suggest that a major involvement of the platelet is likely in human glomerulonephritis both as an initiating agent of injury and in the amplificaPlatelets in prolifeative lupus nephritis 25 1 tion of inflammation. In this study we have demonstrated a correlation between reduced platelet survival and increased platelet localization within the kidney in patients with systemic lupus erythematosus and proliferative glomerulonephritis. The significant shortening in platelet survival noted in our patients with diffuse proliferative glomerulonephritis could be attributed to an anti-platelet factor directed against platelet antigens, such as exists in idiopathic thrombocytopenic purpura (Karpatkin et al., 1972) . This hypothesis is difficult to support in light of the increased renal versus splenic platelet uptake observed in our patients with systemic lupus erythematosus. The patient with the classical platelet autoantibody disease, idiopathic thrombocytopenic purpura, had a shortened survival but his renal platelet localization ratio was markedly reduced. This reduction represented a marked increase in splenic localization, which is in keeping with the findings of Aster & Keene (1969) , who observed predominant splenic localization of platelets in patients with idiopathic thrombocytopenic purpura when survival was greater than 20 min, a pattern characteristic of autoantibody sensitization of platelets and reticuloendothelial uptake. An increase in splenic uptake may occur owing to damage to platelets, antibodies to platelets and hypersplenism. All of these factors were considered to reduce the localization ratio, yet patients with diffuse proliferative nephritis demonstrated a significant increase in renal platelet localization.
The correlation of a shortened platelet survival and increased renal platelet uptake with the diffuse proliferative morphology was striking. It is well established that the classification of renal morphology in the glomerulonephritis of systemic lupus erythematosus provides one of the best prognostic indicators in terms of future renal impairment (Baldwin et al., 1970; Pollack et al., 1964) . Unpublished data on a series of fifty-two patients submitted to biopsy supports this suggestion (J. S. Cameron, unpublished work). Only two of these patients showed a change from minor focal to diffuse proliferative glomerulonephritis within the period of observation.
Most patients with a biopsy showing diffuse proliferative disease develop renal insufficiency within 10 years, whereas the majority of patients with minor or focal proliferative change do not develop marked progressive renal impairment (Baldwin et al., 1970) .
It is obvious from the report by Ginzler, Nicastri, Chen, Friedman, Diamond & Keplan (1974) that the morphological classification in the proliferative nephritis of systemic lupus erythematosus is not always constant, but even in their selected series, the spectrum of progressive renal impairment generally correlated with the biopsy classification.
The intrarenal platelet consumption detected in our patients with diffuse proliferative nephritis may represent a possible mechanism for the continuing insidious scarring which is a feature of this form of nephritis, or it may merely be an epiphenomenon secondary to the pre-existing damage. George, Slichter, Quadracci, Striker & Harker (1974) have recently demonstrated selective platelet consumption in the haemolytic uraemic syndrome, membranoproliferative glomerulonephritis, recent and rejecting kidney transplants, glomerulosclerosis and diabetic nephropathy, which was considered to be secondary to primary intrarenal endothelial damage. Carruthers, Ralfs, Gimlette & Finn (1974) demonstrated a marked shortening in platelet survival in four patients with the diagnosis of acute proliferative nephritis and suggested that this may be associated with platelet aggregation and intraglomerular clotting.
The production of sclerosing glomerular lesions by one episode of ADP-induced intrarenal platelet microaggregation (Jorgensen, Glynn, Hovig, Murphy, Buchanan & Mustard, 1970) does provide evidence that platelets are capable of producing sclerosing lesions which are often considered the hallmark of progressive renal damage in the diffuse proliferative nephritis of systemic lupus erythematosus (Baldwin et al., 1970) . Although we have not defined the interrelationship between immune complex and platelets in the induction and progression of renal damage, the increased renal platelet consumption observed in patients with the progressive form of human immune complex nephritis provides a possible intermediary mechanism via immune complex stimulation of platelet microaggregation for this scarring process.
